Fetal treatment for severe congenital diaphragmatic hernia
Official title: Fetal Endoscopic Tracheal Occlusion (FETO) Trial for Congenital Diaphragmatic Hernia
Run by University of California, Davis · NCT05421676 · Data updated 2026-11-12
This study is testing a new procedure for pregnant women with severe congenital diaphragmatic hernia to see if it can help improve their baby's lung development before birth.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 10 (estimated) |
| Sponsor | University of California, Davis Academic / other |
| Locations | 1 site (Sacramento, California) |
| Status | Recruiting |
| Started | February 12, 2024 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | December 15, 2025 |
| Trial ID | NCT05421676 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are pregnant women aged 18 and older with singleton pregnancies diagnosed with severe CDH and willing to comply with study protocols.
✕Probably not a fit
Patients with major structural cardiac defects or those who do not meet the specific inclusion criteria will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot trial evaluates the feasibility and safety of Fetal Endoscopic Tracheal Occlusion (FETO) using the Goldballoon Detachable Balloon at UC Davis Medical Center. Pregnant women with severe congenital diaphragmatic hernia (CDH) will undergo the procedure between 27 and 29 weeks of gestation. The study aims to monitor the outcomes and safety of this intervention, requiring participants to attend weekly follow-up appointments until delivery. The trial focuses on a specific patient population with severe pulmonary hypoplasia associated with CDH.
Why it matters
Potential benefit: If successful, this treatment could significantly improve outcomes for fetuses diagnosed with severe congenital diaphragmatic hernia.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in treating congenital conditions, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability (meets psychosocial criteria below) for the duration of the study 3. Pregnant women, age 18 years and older 4. Singleton pregnancy 5. No pathogenic variants on microarray or pathologic findings on karyotype 6. Fetal echocardiogram with changes expected with CDH and no major structural cardiac defects 7. Fetal CDH (left or right) with severe pulmonary hypoplasia, defined as o/e LHR \<25% with liver up 8. Gestational age at FETO procedure: if o/e LHR \<25% will be done at 27 weeks plus 0 days to 29 weeks plus 6 days 9. Meets psychosocial criteria * Willing to reside within 30 minutes of UC Davis Medical Center and ability to maintain follow up appointments * Patient has a support person (e.g. spouse, partner, friend, parent) that is available to stay with her for the duration of the pregnancy near the UC Davis Medical Center. * Willing to comply with restrictions of daily living including inability to exercise, have intercourse, or return to work Exclusion Criteria: 1. Adults unable to consent 2. Prisoners 3. Multi-fetal pregnancy 4. History of latex allergy 5. History of preterm labor or incompetent cervix (requiring cerclage), short cervix (\<20mm), or uterine anomaly predisposing to preterm labor 6. Psychosocial ineligibility * Inability to reside within 30 minutes of UC Davis Medical Center or inability to maintain follow up appointments * Social work will meet with each patient to evaluate the social situation and support system. Identifiable issues of social instability or compliance with the protocol will exclude her as a potential candidate. 7. Bilateral CDH, unilateral CDH with o/e LHR \> 25% or unilateral CDH with o/e LHR \<25% but liver completely down in abdomen 8. Additional fetal or genetic abnormalities that would impact care after delivery or be known to have an impact on outcome 9. Maternal contraindications to elective fetoscopic surgery 10. Significant placental abnormalities (abruption, chorioangioma, accreta) known at time of enrollment and/or surgery 11. Maternal isoimmunization or neonatal alloimmune thrombocytopenia 12. Maternal HIV, Hepatitis B with positive surface antigen, Hepatitis C with presence of virus in maternal blood due to risk of fetal transmission during the procedure 13. No safe or feasible fetoscopic approach to balloon placement
Where it's running
-
UC Davis Medical Center
Sacramento, California, United States Recruiting
Study contacts
- Study coordinator: Amy Powne, MSN, RN
- Email: fctc@ucdavis.edu
- Phone: 916-717-4690
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Melatonin plus inhaled nitric oxide for pulmonary hypertension in full-term newborns
This study tests whether adding melatonin to inhaled nitric oxide helps treat pulmonary hypertension in full-term neonates.
-
FETO with a Goldballoon device for fetuses with diaphragmatic hernia
This study tests whether performing Fetoscopic Endoluminal Tracheal Occlusion on pregnancies with fetal diaphragmatic hernia improves baby survival and reduces long-term problems.
-
Fetal tracheal occlusion (FETO) for severe congenital diaphragmatic hernia
This trial will test whether fetal endoluminal tracheal occlusion (FETO) helps fetuses with severe congenital diaphragmatic hernia and intrathoracic liver herniation survive to hospital discharge.
-
Long-term outcomes after FETO for severe left or right congenital diaphragmatic hernia
This trial will test whether performing FETO in fetuses with isolated severe left or right CDH helps more babies survive to hospital discharge and have fewer long-term problems than standard care.
-
Fetal treatment for congenital diaphragmatic hernia
This study is testing a new way to treat congenital diaphragmatic hernia in unborn babies by placing a balloon in their airway to help their lungs grow before they are born.
-
Fetoscopic balloon (FETO) for severe left and right congenital diaphragmatic hernia — long-term outcomes
This trial will try placing and later removing a tiny balloon in the fetal windpipe around 27–29 weeks to help babies with severe congenital diaphragmatic hernia and liver herniation survive the newborn period.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.